ABS14RACT Rates of purine synthesis de novo, as measured by the incorporation of [4C]formate into newly synthesized purines, have been determined in cultured human fibroblasts derived from normal individuals and from patients deficient in adenosine deaminase, purine nucleoside phosporylase, or hypoxanthine phosphoribosyltransferase, three consecutive enzymes of the purnne salvage pathway. All four types of cell lines are capable of incorporating [14C]formate into purines at approximately the same rate when the assays are conducted in purine-free medium. The purine overproduction that is characteristic of a deficiency in either the transferase or the phosphorylase and that results from a block in purine reutilization can be demonstrated by the resistance of [14Clformate incorporation into purines to inhibition by hypoxanthine in the case of hypoxanthine phosphoribosyltransferase-deficient fibroblasts and by resistance to inhibition by inosine in the case of purine nucleoside phosphorylast-deficient fibroblasts. Human cells in culture utilize purines derived from two metabolic routes-either by synthesis de nowo beginning with 5-phosphoribosyl-1-pyrophosphate (PP-ribose-P) and glutamine or by "salvage" from PP-ribose-P and purines present in the medium or arising from the intracellular degradation of nucleic acids. Individuals who lack purine nucleoside phosphorylase (PNP) or hypoxanthine phosphoribosyltnferase (HPRT), two consecutive enzymes of the purine salvage pathway, synthesize purines de novo at an accelerated rate (1-3). Although several cell culture systems have been devised to demonstrate the purine overproduction characteristic of patients with a deficiency of HPRT (4-8), none has been devised to show the comparable overproduction in PNP deficiency. The mechanism by which the rate of purine synthesis de novo is controlled has been the subject of intensive study by numerous investigators. It is believed to involve the regulation of PP-ribose-P synthetase or PP-ribose-P amidotransferase, the enzymes which catalyze the first two reactions of this pathway. In Ehrlich ascites tumor cells, the rate of synthesis of PP-ribose-P has been shown to be inversely related to the concentration of adenine and guanine nucleotides (9). Partially purified human PP-ribose-P synthetase has been shown to be inhibited by ADP and AMP (10). The activity of PP-ribose-P amidotransferase and of the de novo pathway as a whole may be controlled by the intracellular levels of PP-ribose-P and of adenine and guanine nucleotides (4, (11) (12) (13) (14) (15) (16) . PP-ribose-P is normally present at concentrations well below the Km for the enzyme. It also converts the human enzyme to its more active, low molecular weight form. Adenine and guanine nucleotides act as inhibitors of the partially purified enzyme and also convert the human enzyme to its less active, high molecular weight form. Thus, either an increase in the concentration of PP-ribose-P or a decrease in the levels of inhibitory nucleotides could potentially accelerate the rate of purine synthesis de novo and result in purine "overproduction." This communication concerns the study of purine metabolism in cultured human fibroblasts deficient in each of three enzymes of the purine salvage pathway and attempts to define better a "normal" rate of purine synthesis de novo as compared to purine "overproduction." In particular, we have attempted to rectify the previously reported discrepancy in rates of purine synthesis de now in patients deficient in PNP and in their cultured cells (1).
ABS14RACT Rates of purine synthesis de novo, as measured by the incorporation of [4C] formate into newly synthesized purines, have been determined in cultured human fibroblasts derived from normal individuals and from patients deficient in adenosine deaminase, purine nucleoside phosporylase, or hypoxanthine phosphoribosyltransferase, three consecutive enzymes of the purnne salvage pathway. All four types of cell lines are capable of incorporating [14C] formate into purines at approximately the same rate when the assays are conducted in purine-free medium. The purine overproduction that is characteristic of a deficiency in either the transferase or the phosphorylase and that results from a block in purine reutilization can be demonstrated by the resistance of [14Clformate incorporation into purines to inhibition by hypoxanthine in the case of hypoxanthine phosphoribosyltransferase-deficient fibroblasts and by resistance to inhibition by inosine in the case of purine nucleoside phosphorylast-deficient fibroblasts. Human cells in culture utilize purines derived from two metabolic routes-either by synthesis de nowo beginning with 5-phosphoribosyl-1-pyrophosphate (PP-ribose-P) and glutamine or by "salvage" from PP-ribose-P and purines present in the medium or arising from the intracellular degradation of nucleic acids. Individuals who lack purine nucleoside phosphorylase (PNP) or hypoxanthine phosphoribosyltnferase (HPRT), two consecutive enzymes of the purine salvage pathway, synthesize purines de novo at an accelerated rate (1-3). Although several cell culture systems have been devised to demonstrate the purine overproduction characteristic of patients with a deficiency of HPRT (4) (5) (6) (7) (8) , none has been devised to show the comparable overproduction in PNP deficiency. The mechanism by which the rate of purine synthesis de novo is controlled has been the subject of intensive study by numerous investigators. It is believed to involve the regulation of PP-ribose-P synthetase or PP-ribose-P amidotransferase, the enzymes which catalyze the first two reactions of this pathway. In Ehrlich ascites tumor cells, the rate of synthesis of PP-ribose-P has been shown to be inversely related to the concentration of adenine and guanine nucleotides (9) . Partially purified human PP-ribose-P synthetase has been shown to be inhibited by ADP and AMP (10) . The activity of PP-ribose-P amidotransferase and of the de novo pathway as a whole may be controlled by the intracellular levels of PP-ribose-P and of adenine and guanine nucleotides (4, (11) (12) (13) (14) (15) (16) . PP-ribose-P is normally present at concentrations well below the Km for the enzyme. It also converts the human enzyme to its more active, low molecular weight form. Adenine and guanine nucleotides act as inhibitors of the partially purified enzyme and also convert the human enzyme to its less active, high molecular weight form. Thus, either an increase in the concentration of PP-ribose-P or a decrease in the levels of inhibitory nucleotides could potentially accelerate the rate of purine synthesis de novo and result in purine "overproduction." This communication concerns the study of purine metabolism in cultured human fibroblasts deficient in each of three enzymes of the purine salvage pathway and attempts to define better a "normal" rate of purine synthesis de novo as compared to purine "overproduction." In particular, we have attempted to rectify the previously reported discrepancy in rates of purine synthesis de now in patients deficient in PNP and in their cultured cells (1).
The three enzyme deficiencies studied are: HPRT, PNP, and adenosine deaminase (ADA). A lack of the enzyme HPRT (17) leads to the Lesch-Nyhan syndrome (2) with its characteristic neurological dysfunction and purine overproduction de novo resulting in pronounced hyperuricemia. A lack of PNP (18) results in an immunodeficiency disease with a specific defect in T-cell function as well as purine overproduction de novo; however, hypouricemia rather than hyperuricemia is seen because purine catabolism stops with the formation of purine nucleosides. Large quantities of inosine and guanosine and smaller amounts of the corresponding deoxynucleosides are excreted in the urine (1, 3). ADA deficiency leads to a severe combined immunodeficiency with T-cell and usually B-cell dysfunction (19) . No purine overproduction has been found in patients lacking ADA (20) .
MATERUILS AND METHODS
Source and Growth of Cells. Fibroblasts were grown from foreskins obtained from apparently normal male infants or from skin biopsies obtained from normal volunteers or from patients deficient in HPRT, ADA (20) , or PNP (3). Fibroblast cultures were routinely maintained in Eagle's minimal essential medium supplemented with 10% fetal calf serum, 2 mM glutamine, penicillin (100 units/ml), and streptomycin (100 ,ug/ml). In some experiments, the medium was supplemented with fetal calf serum that had been extensively dialyzed against 0.9% NaCl. Low serum medium contained AutoPow minimal essential medium (Flow Laboratories), supplemented with 0.1% fetal calf serum, 2 mM glutamine, penicillin (100 units/ml), streptomycin (100 ;g/ml), 4% bovine serum albumin, transferrin (5'Mg/ml), and 4% (vol/vol) Coon's F-12 medium (minus hypoxanthine, thymidine, and folic acid) (21) Fig. 4 . By using this medium, PNP-and normal fibroblasts could be distinguished based upon the degree of inhibition of [14C]formate incorporation into purines caused by 50 MM inosine; the PNP-fibroblasts were highly resistant (Fig. 5) . Adenosine (50M'M) caused (31) and others (4, 32) have measured the intracellular concentrations of purine nucleotides in normal and HPRT-deficient fibroblasts and lymphoblasts and have found no evidence for decreased concentrations of adenine and guanine nucleotides in cells that lack HPRT. However, the concentrations of AMP and GMP, the most potent inhibitors of the amidotransferase, have not been precisely determined because they are very close to the detection limits of the methods available. Furthermore, the existence of separate compartmentalized pools of adenine and guanine nucleotides that may be inhibitory to the amidotransferase must be considered. Additional experiments need to be designed which will allow alterations in the intracellular concentrations of potentially inhibitory nucleotides independently from changes in the concentration of PP-ribose-P, so that the relative importance of these two factors in controlling the rate of purine synthesis de novo may be evaluated. Our finding that neither methylene blue nor inosine increased the rate of ["4C]formate incorporation into purines in Lesch-Nyhan cells is consistent with Hershfield's (29) findings that indicate that there may be conditions where the concentration of PP-ribose-P is not rate-limiting for purine synthesis de novo (12, 27 broblasts is consistent with the observation that patients who lack ADA do not overproduce purines de now (20) and suggests that adenosine can be effectively metabolized via adenosine inase. In conclusion, we feel that purine overproduction in the above mutations can best be demonstrated by the resistance of purine synthesis de novo to potentially inhibitory purine nucleosides and bases, rather than by the absolute rate of incorporation of ["4C]formate into purines.
